Literature DB >> 16042676

Profound weight loss associated with reboxetine use in a 44-year-old woman.

T Y-T Lu1, A Kupa, G Easterbrook, A A Mangoni.   

Abstract

We report a case of significant weight loss experienced by a 44-year-old Caucasian woman treated with reboxetine. She was treated with this drug at 12 mg daily for a total duration of 11 months. During the corresponding period her body mass index (BMI) decreased from a baseline of 21.4 kg m(-2) to a low of 16.8 kg m(-2). Withdrawal of the drug led to a full recovery of her BMI. The strongest evidence linking reboxetine to this woman's weight loss laid in the fact that the re-introduction of the drug subsequently caused a similar negative impact in her BMI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042676      PMCID: PMC1884922          DOI: 10.1111/j.1365-2125.2005.02407.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

Review 1.  Metabolic drug interactions with new psychotropic agents.

Authors:  Edoardo Spina; Maria Gabriella Scordo; Concetta D'Arrigo
Journal:  Fundam Clin Pharmacol       Date:  2003-10       Impact factor: 2.748

Review 2.  Reboxetine: a norepinephrine selective reuptake pump inhibitor.

Authors:  Sheldon H Preskorn
Journal:  J Psychiatr Pract       Date:  2004-01       Impact factor: 1.325

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

4.  Reboxetine in the treatment of bulimia nervosa: a report of seven cases.

Authors:  N El-Giamal; M de Zwaan; U Bailer; C Lennkh; P Schüssler; A Strnad; S Kasper
Journal:  Int Clin Psychopharmacol       Date:  2000-11       Impact factor: 1.659

5.  Use of reboxetine in bulimia nervosa: a pilot study.

Authors:  Secondo Fassino; Giovanni Abbate Daga; Sonia Boggio; Lorenzo Garzaro; Andrea Pierò
Journal:  J Psychopharmacol       Date:  2004-09       Impact factor: 4.153

Review 6.  The pharmacology of human appetite expression.

Authors:  Jason C G Halford; Gillian D Cooper; Terence M Dovey
Journal:  Curr Drug Targets       Date:  2004-04       Impact factor: 3.465

7.  Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.

Authors:  Michael Poyurovsky; Ilanit Isaacs; Camil Fuchs; Michael Schneidman; Sarit Faragian; Ronit Weizman; Abraham Weizman
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

  7 in total
  1 in total

Review 1.  Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis.

Authors:  Yun-Jung Choi
Journal:  ScientificWorldJournal       Date:  2015-01-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.